



→

PTO/SB/08B (10-01)

+

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/627,439	
			Filing Date	July 25, 2003	
			First Named Inventor	Kenneth T. RICHARDSON et. al.	
			Art Unit	To Be Assigned	
			Examiner Name	To Be Assigned	
Sheet	1	of	2	Attorney Docket Number	017380-000313US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GR	1	US-4,937,234	06-26-1990	Fahim	
	2	US-5,599,719	02-04-1997	Woiszwilllo et al.	
	3	US-5,804,594	09-08-1998	Murad	
	4	US-5,962,030	10-05-1999	Fine	
	5	US-6,133,318	10-17-2000	Hart	
GN	6	US-6,235,756	05-22-2001	D'Amato	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code* (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GN	7	ALGERT, S.J. et al. "Assessment of dietary intake of lysine and arginine in patients with herpes simplex," J. Amer. Diet Assoc. 1987, pp. 1560-1561, Vol. 87, No. 11.	
	8	AYALA, E. and KRIKORIAN, D. "Effect of L-lysine monohydrochloride on cutaneous herpes simplex virus in the guinea pig," J. Med. Virol. 1989, pp. 16-20, Vol. 28.	
	9	EBY, G.A. and HALCOMB, W.W. "Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols," Med. Hypotheses 1985, pp. 157-165, Vol. 17.	
	10	KAUL, T.N. et al. "Antiviral effect of flavonoids on human viruses," J. Med. Virol. 1985, pp. 71-79, Vol. 15.	
	11	KNOWLES, R.W. and PERSON, S. "Effects of 2-deoxyglucose, glucosamine, and mannose on cell fusion and the glycoproteins of herpes simplex virus," J. Virol. 1976, pp. 644-651, Vol. 18, No. 2.	

Examiner Signature		Date Considered	3/5/07
-----------------------	--	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60012807 v1



→

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/627,439
Filing Date	July 25, 2003
First Named Inventor	Kenneth T. RICHARDSON et. al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	017380-000313US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QR	12	KUMEL, V.G. et al. "[Zinc sulfate and heparin for local therapy of herpes. Antiherpetic drugs, not leading to selection of HSV variants]," <i>Fortschr. Med.</i> 1995, pp. 235-238, Vol. 113, No. 15.	
	13	MARTIN, C.P. et al. "Antiviral activity of a D-glucosamine derivative against herpetic ulcers (HSV type 2) in rabbit cornea," <i>Acta. Ophthalmol. (Copenh.)</i> 1989, pp. 55-60, Vol. 67.	
	14	PALAMARA, A.T. et al. "Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication," <i>Antiviral Res.</i> 1995, pp. 237-253, Vol. 27.	
	15	RAMOS-KURI, M. et al. "Inhibition of three alphaherpesviruses (herpes simplex 1 and 2 and pseudorabies virus) by heparin, heparan and other sulfated polyelectrolytes," <i>Arch. Med. Res.</i> 1996, pp. 43-48, Vol. 27, No. 1.	
	16	SAGRIPANTI, J.L. et al. "Mechanism of copper-mediated inactivation of herpes simplex virus," <i>Antimicrob. Agents Chemother.</i> 1997, pp. 812-817, Vol. 41, No. 4.	
	17	VOSEN, R.C. et al. "Intracellular thiol redox status affects rat cytomegalovirus infection of vascular cells," <i>Virus Res.</i> 1997, pp. 173-183, Vol. 48.	
QR	18	WHITE, L.A. et al. "In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses," <i>J. Clin. Microbiol.</i> 1986, pp. 527-531, Vol. 24, No. 4.	

Examiner
SignatureDate
Considered

3/5/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60012807 v1